Telix Pharmaceuticals was created to deliver on the promise of nuclear medicine
The field of nuclear medicine has historically lacked clinical momentum and commitment to late-stage product development. Our goal is to rectify this for the benefit of patients.
Telix and University of Queensland-led Consortium Awarded $5M Australian Research Council (ARC) Grant
Melbourne – 8 August 2022. Telix and University of Queensland-led Consortium Awarded $5M Australian Research Council (ARC) Grant
Telix 1H 2022 Financial Results and Company Update Investor Call
Melbourne (Australia) – 4 August 2022. Telix to hold investor conference call to present 1H 2022 financial results and Company...
BAMF Health and Telix complete first total-body PET scans with Illuccix for prostate cancer imaging
GRAND RAPIDS, Michigan and INDIANAPOLIS, Indiana – 27 July 2022. Telix and BAMF Health use Illuccix® for the first time with...
Activities Report and Appendix 4C for June 2022 Quarter
Melbourne (Australia) – 21 July 2022. Telix issues Appendix 4C quarterly cash flow statement and accompanying Activities Report for the...